|
Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Invectys; Merck; Nestle health science; Roche |
Speakers' Bureau - Invectys |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche |
|
|
|
Travel, Accommodations, Expenses - Hospira |
|
|
Research Funding - Merck Serono (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Roche |
|
|
Consulting or Advisory Role - Ipsen |
Travel, Accommodations, Expenses - Amgen; Ipsen; Novartis; Sanofi |
|
Olivier Jean Marie Dupuis |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Amgen; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Roche |
Speakers' Bureau - Lilly; Novartis; Pierre Fabre |
Research Funding - Boehringer Ingelheim |
Travel, Accommodations, Expenses - Lilly; Roche |
|
|
|
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Sanofi |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER |
Speakers' Bureau - Amgen; Baxalta; Lilly; Merck; Roche/Genentech; Sanofi; SERVIER |